Specific eosinophilia syndrome, for patients without any symptoms as well as tissue and organ damage, can be closely observed and followed up; for patients with positive FIP1L1-PDGFRA fusion gene, they can be treated with imatinib and glucocorticoids. 1. Imatinib: The U.S. Food and Drug Administration (FDA) recommends treatment with imatinib. The dose of imatinib can be tapered after complete hematologic remission is achieved, keeping the maintenance dose. Imatinib can have adverse reactions such as rash and diarrhea; it is contraindicated in patients who are allergic to the active substance within the imatinib drug. 2. Glucocorticoid: Glucocorticoid therapy should be given a few days before the application of Imatinib to prevent acute myocardial infarction. The use of appropriate drugs such as prednisone can be treated in accordance with medical advice. Long-term use can occur medical Cushing’s syndrome, weight gain, lower extremity swelling, easy bleeding and other adverse reactions; allergy to steroid hormones is prohibited. Patients with specific eosinophilia syndrome are advised to go to the hospital in time, improve the examination to clarify the cause of the disease, and then give targeted treatment or therapy. The use of drugs must follow the doctor’s instructions, not blindly use their own drugs, so as not to cause adverse consequences.